COMP <GO>
CRL vs MRK // EV/EBITDA & P/E VALUATION
Charles River Laboratories International Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CRL 2
— MRK 13
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
valuation
95.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 20.70% | -20.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 3.42% | -0.32 | MRK | /fcf-yield <GO> |
| Operating Margin | 0.60% | 34.30% | -33.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 28.10% | -31.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 1.30% | -2.20 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 5.19 | -1.54 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 56.9 | +11.19 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 18.4x | +4.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $361.02B | -$343.07B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | MRK REV | CRL GROSS % | MRK GROSS % | CRL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $65.01B | 44.0% | 74.8% | $557.0M | $12.36B |
| FY 2024 | $4.05B | $64.17B | 44.0% | 76.3% | $552.3M | $18.10B |
| FY 2023 | $4.13B | $60.12B | 44.0% | 44.0% | $498.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
MRK // BETA 0.92